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A family history of coronary artery disease (CAD), especially when the disease occurs at a young age, is a potent
risk factor for CAD. DNA collection in families in which two or more siblings are affected at an early age allows
identiﬁcation of genetic factors for CAD by linkage analysis. We performed a genomewide scan in 1,168 individuals
from 438 families, including 493 affected sibling pairs with documented onset of CAD before 51 years of age in
men and before 56 years of age in women. We prospectively deﬁned three phenotypic subsets of families: (1) acute
coronary syndrome in two or more siblings; (2) absence of type 2 diabetes in all affected siblings; and (3) atherogenic
dyslipidemia in any one sibling. Genotypes were analyzed for 395 microsatellite markers. Regions were deﬁned as
providing evidence for linkage if they provided parametric two-point LOD scores 11.5, together with nonparametric
multipoint LOD scores 11.0. Regions on chromosomes 3q13 (multipoint LOD p 3.3; empirical P value !.001)
and 5q31 (multipoint LOD p 1.4; empirical P value !.081) met these criteria in the entire data set, and regions
on chromosomes 1q25, 3q13, 7p14, and 19p13 met these criteria in one or more of the subsets. Two regions,
3q13 and 1q25, met the criteria for genomewide signiﬁcance. We have identiﬁed a region on chromosome 3q13
that is linked to early-onset CAD, as well as additional regions of interest that will require further analysis. These
data provide initial areas of the human genome where further investigation may reveal susceptibility genes for early-
onset CAD.
Introduction
More than 13 million Americans are afﬂicted with clin-
ically signiﬁcant coronary artery disease (CAD) (Amer-
ican Heart Association 2004), and the care of these pa-
tients costs 1$133 billion annually. Of these Americans
with CAD, ∼10% are !54 years of age. Although a
minority of the patient base, this 10% represents a fertile
group for the investigation of the genetics underlying
cardiac risk, since a family history of CAD is one of the
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most robust risk factors for the disease, even after ad-
justment for environmental risks that may be shared
within families (Shea et al. 1984). Additionally, the dis-
ease inﬂicts a particularly high economic impact on this
group of patients with early-onset CAD. The identiﬁ-
cation of genetic markers for the predisposition to de-
velop CAD is likely to lead to new insights into the
pathophysiology of the disease and the development of
therapeutic agents for the prevention and treatment of
CAD. There are two possible advantages to studying
families with more than one member affected at an early
age: (1) a more etiologically homogeneous sample will
be ascertained, and (2) the genetic effect should be
stronger in these families.
Several studies have estimated that the relative risk
of developing early-onset CAD in a ﬁrst-degree relative
(sib) is between 3.8 and 12.1, depending on the age at
Hauser et al.: Genomewide Scan for Early-Onset CAD 437
Table 1
Distribution of Families Included in the GENECARD Genome Screen across the Six International Ascertainment Sites
Ascertainment Site No. of Families No. of ASPs No. of Individuals
No. of Affected
Individuals
Princess of Wales Hospital (Cardiff, United Kingdom) 62 (39, 21, 24) 64 135 128
Duke University Medical Center (Durham, NC) 194 (95, 78, 46) 223 599 462
Ludwigshafen Heart Center (Ludwigshafen, Germany) 24 (12, 5, 6) 24 48 48
Lausanne University Hospital (Lausanne, Switzerland) 50 (25, 13, 20) 51 103 103
Vanderbilt University (Nashville, TN) 45 (25, 18, 22) 67 144 117
University of Shefﬁeld (Shefﬁeld, United Kingdom) 63 (32, 17, 28) 64 139 127
Total 438 493 1,168 985
NOTE.—Numbers in parentheses reﬂect the number of families in the subsets of patients with ACS, NDIA, and ADL, respectively.
onset of the proband (Rissanen 1979; Shea et al. 1984).
Twin studies have shown increased risk to MZ and DZ
twins, with elevated risk to the co-twin when the index
twin was !65 years of age (Marenberg et al. 1994).
Although family history has been consistently identiﬁed
as an important risk factor in many independent studies,
there are many other individual-speciﬁc factors that in-
crease the risk of CAD, including lipid abnormalities of
several kinds, smoking, hypertension, diabetes, physical
inactivity, and obesity. These risk factors exhibit strong
concordance in families and may add to the familial
mechanism of CAD. In a population-based study of
503 Australian families, Harrap et al. (2000) identiﬁed
shared environmental effects that persisted into adult-
hood, particularly body mass index. Furthermore, some
risk factors themselves may exhibit signiﬁcant familial
clustering, including dyslipidemia, obesity, and diabetes
(Perusse et al. 1997; Rice et al. 1997; Katzmarzyk et al.
2000; Watanabe et al. 2000). The importance of these
risk factors in the etiology of CAD suggests that they
must be considered in studies identifying genes for CAD.
The list of previously implicated candidate genes for
CAD is long and includes polymorphisms in various
genes plausibly associated with CAD (Lusis et al. 1992;
Breslow 2000; Lusis 2000; Yamada et al. 2002). Re-
cently, Yamada et al. (2002) genotyped thousands of
individuals with CAD for 71 genes, and Ozaki et al.
(2002) genotyped hundreds of individuals for thousands
of SNPs. In both of these large-scale candidate-gene
studies, only a few SNPs were shown to be associated
in a second set of patients. Despite the considerable re-
sources devoted to the study of candidate genes as risk
factors for CAD, none have been shown to account for
even a modest fraction of the familial risk of CAD.
Thus, there is a need for a complementary genomewide
approach that is unbiased with respect to gene function.
Here we report the results of a genomewide scan for
genetic regions linked to early-onset CAD by use of data
from 438 families with two siblings who had CAD di-
agnosed before the age of 51 years in men and 56 years
in women.
Material and Methods
Clinical Data Collection
The GENECARD study design has been described else-
where (Jomini et al. 2002; Hauser et al. 2003). In brief,
probands were ascertained by investigators afﬁliatedwith
six international clinical centers: Duke UniversityMedical
Center (United States), University of Shefﬁeld (United
Kingdom), University of Wales College of Medicine (Uni-
ted Kingdom), University of Lausanne (Switzerland),
Ludwigshafen Heart Center (Germany), and Vanderbilt
University (United States). Study protocol and data-shar-
ing agreements were approved by the institutional re-
view boards of each participating institution. Informed
consent was obtained from each participant.
Individuals were recruited if they met the diagnostic
criteria for CAD and if the disease had been diagnosed
before the age of 51 years in men and 56 years in women.
These age limits were based on the incidence curves of
CAD and the estimates of genetic effect at various ages
(Rissanen 1979; Shea et al. 1984; Marenberg et al.
1994). To be eligible for participation in the GENE-
CARD study, families were required to have at least two
living siblings who met the robust diagnostic criteria.
Living parents of the affected sibling pair (ASP) and
additional affected siblings were ascertained when avail-
able. Family members (and connecting relatives) outside
the proband’s nuclear family were also considered to be
affected if they met the diagnostic and age criteria for
inclusion in GENECARD. Any sample with a sibling
with an age at onset older than the age criteria was
included for the purpose of estimating identity-by-de-
scent sharing but was not considered to be affected.
Blood samples were obtained by study staff at the med-
ical center or clinic, by visiting participants’ homes, or,
in a few cases, by mail. Medical history and risk-factor
information were obtained by interviewing patients and
by abstracting information from medical records. Table
1 shows the number of families, individuals, and ASPs
included in the GENECARD sample. There were 493
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independent ASPs in the 438 families: 395 families with
two affected siblings, 36 families with three affected sib-
lings, and 7 families with four or more affected siblings.
As with other adult-onset diseases, a signiﬁcant number
of parents could not be ascertained; only 19 fathers and
62 mothers of the ASPs are included in the genome
screen.
We established a stringent deﬁnition of CAD to ensure
accurate diagnosis and to reduce possible misclassiﬁca-
tion, as described by Hauser et al. (2003). In addition
to meeting the GENECARD sex-speciﬁc age criteria, pa-
tients were required to have diagnoses accompanied by
an index event—coronary angiography, myocardial in-
farction (MI), coronary artery bypass graft, or a func-
tional test documenting reversible myocardial ischemia
(Hauser et al. 2003)—veriﬁed through medical record
evidence. A system of periodic review was implemented
to establish quality control (QC) and to ensure consis-
tency among all clinical sites. At 6-mo intervals during
ascertainment, a random sample of 10% of the families
was selected, and a complete review of the diagnosis and
the information supporting that diagnosis was per-
formed by the GENECARD cardiologists. As evidence
of the success of this effort, the clinical characteristics
of affected individuals were remarkably similar across
all collection sites (Hauser et al. 2003).
Laboratory Methods
DNA was extracted by use of the Puregene system
(Gentra Systems). The DNA samples from the study sub-
jects were organized into genotyping lists, producing a
standardized order of samples; QC samples were incor-
porated at speciﬁed slots in the list. The laboratory tech-
nicians were blinded to the identity of the QC samples
and were also blinded to affection status and family
composition of all samples. Genotyping was performed
by use of the gel-based FAAST method (Vance and Ben
Othmane 1998). Multiplex reactions were used to in-
crease efﬁciency, lower the cost, and increase the speed
of the genomic screens. Two-color ﬂuorescence allowed
for the combination of two multiplex sets of genomic
markers in the same lane (Vance et al. 1996).
We implemented a series of QC checks to maximize
data quality during genotyping. Two control individuals
common to all gels, as well as six duplicated QC samples
from the GENECARD study, were included for each set
of 84 samples. QC mismatches identiﬁed technical dif-
ﬁculties or systematic marker-reading errors that were
resolved prior to analysis. Each marker was tested for
deviations from Hardy-Weinberg equilibrium (HWE) in
the 438 probands, with particular attention given to de-
viations from the expected rate of homozygosity. Mark-
ers that showed deviations from HWE were examined
for technical problems, such as the presence of a null
allele. A total of 395 (98.3%) of 402 markers attempted
passed the QC tests and were included in the genome
screen analysis. The mean genotyping efﬁciency (pro-
portion of nonzero genotypes over the 395 markers) was
97.6%. By use of data from several large studies per-
formed at the Duke Center for Human Genetics, we
estimated an error rate in sample processing and allo-
cation of 0.14%, and we estimated the genotyping error
rate to be ∼0.8%.
The program PedCheck (O’Connell and Weeks 1998)
was used to identify Mendelian inconsistencies. If an
inconsistency persisted after rereading of the gel, the ge-
notypes for that marker were removed for the entire
family. If the family had multiple pedigree inconsisten-
cies involving 10 markers, the family was removed
from analysis. Since the majority of GENECARD fam-
ilies were ASPs without parents, pedigree error detection
by use of Mendelian inheritance inconsistencies was lim-
ited. To overcome this limitation, we used the RELPAIR
software package (Boehnke and Cox 1997; Epstein et
al. 2000) on 395 markers. RELPAIR identiﬁed the likely
biological relationship between pairs of individuals by
use of the entirety of the marker data. A total of 24
families with misspeciﬁed relationships were identiﬁed
in the GENECARD genome screen set. Of these families,
10 were also identiﬁed with Mendelian inconsistencies
by use of PedCheck. The remaining 14 families (3.2%)
were single ASPs that were identiﬁed as likely half-sibling
pairs. After all pedigree QC checks, pedigrees were cor-
rected on the basis of pedigree drawings for six families.
Eighteen families were removed from the data set, leav-
ing 420 families for the ﬁnal analysis.
The families were collected from six sites in the United
States and Europe. It is possible that they represent ge-
netically distinct subpopulations. To test for population
substructure, we used themethods implemented in Struc-
ture (Pritchard et al. 2000) and in Arlequin (Schneider
et al. 2000), by use of an indicator for each site. There
was no evidence from either analysis that the sites could
be distinguished on the basis of allele frequencies at the
395 markers in the genome scan. On the basis of these
results, we estimated allele frequencies from the family
members in the entire sample, as suggested by Broman
(2001). The majority of families were white (np 391
[93.1%]). Small numbers of families prevented analysis
of each ethnic group separately, but we performed a
genome screen with samples from only the white fam-
ilies. Results from this analysis were very similar to the
results for all families, and thus we report the linkage
results for all families combined.
The genetic complexity of CAD required a multi-an-
alytic strategy that would capture all of the linkage in-
formation in the families. We used Genehunter-Plus
(Kong and Cox 1997) for nonparametric nuclear-family
analysis, and VITESSE (O’Connell andWeeks 1995) and
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HOMOG (Ott 1991) were used for two-point affected
individuals–only parametric linkage analysis incorpo-
rating genetic heterogeneity (MLOD). Two parametric
models were used: a recessive model with a disease-allele
frequency of 0.20 and a rare dominant model with a
disease-allele frequency of 0.01. TheMLODwas deﬁned
as the maximum from these two models. Multipoint
linkage analysis was performed by use of Genehunter-
Plus (LOD*) (Kong and Cox 1997). The Marshﬁeld ge-
netic linkage maps were used to estimate intermarker
distances (Broman et al. 1998). We compared results
from all analyses to assess the consistency in linkage
evidence. We deﬁned our most interesting regions as
those with parametric two-point MLOD results 11.5
and nonparametric multipoint LOD* results 11.0 (Hau-
ser et al. 1996; Holmans and Craddock 1997). In ad-
dition, we required that the MLOD and LOD* results
be within 5 cM of each other. The LOD score cut points
we chose were lower than the LOD scores deﬁned by
Lander and Kruglyak (1995) as meeting a genome-
wide signiﬁcance level ( ; ), which5LOD 1 3.6 P ! 2# 10
is known to be conservative (Holmans and Craddock
1997). We chose lower LOD score cut points to avoid
excluding any important loci in the ﬁrst stage of the
analysis, even though this meant accepting the risk of
including some false-positive regions in the follow-up
analyses. To further evaluate the signiﬁcance of regions
meeting our LOD score cutoffs, we used the pairs-score
LOD score statistic implemented in Merlin (Abecasis et
al. 2002), and we used SIMLA (Bass et al. 2004) with
Genehunter-Plus (Kong and Cox 1997) to estimate em-
pirical P values by use of the observed family structures,
marker-allele frequencies, marker-map parameters, and
missing-data patterns. Both methods of estimating the
P values gave consistent results. However, since the use
of SIMLA together with Genehunter-Plus for analysis is
under development, we report the Merlin empirical P
values. To evaluate genomewide signiﬁcance, we used a
method of locus counting that counts the number of
independent linkage regions (ILR) above a speciﬁed
LOD score threshold for each genome screen (Wiltshire
et al. 2002). For the 1,000 data sets simulated byMerlin
from the null hypothesis of no linkage, we estimated the
LOD score at which 5% of the replicates had no more
than 1 ILR.
To reduce etiologic heterogeneity due to phenotypic
characteristics or the presence of other genetic risk fac-
tors and to be able to compare our results to other pub-
lished genome screens, three phenotypic stratiﬁcations
of our families were developed by the investigators prior
to the linkage analysis. These stratiﬁcations were also
chosen to isolate what may be major etiologic classi-
ﬁcations of CAD (e.g., acute coronary syndrome vs. sta-
ble occlusive coronary disease, coronary disease not as-
sociated with diabetes, and CAD associated with
atherogenic dyslipidemias). We deﬁned three subgroups
to attempt to isolate CAD-speciﬁc effects and to match
other patient populations: (1) presence of acute coronary
syndrome (ACS), deﬁned as diagnosis of MI or unstable
angina, in at least two affected siblings (228 families);
(2) presence of atherogenic dyslipidemia (ADL) (Grundy
1995), deﬁned as concomitant presence of plasma tri-
glyceride levels above the 75th percentile for age and
sex and high-density lipoprotein (HDL) cholesterol lev-
els below the 25th percentile for age and sex, in at least
one member of the nuclear family (146 families); and
(3) no diabetes in any affected member of the family
(NDIA) (274 families). There is overlap, in that some
families appear in more than one group, with 50 families
in all groups. However, there was no evidence for as-
sociation of any pair of strata among the families (P 1
for all comparisons). The linkage analysis of CAD.34
was performed in each of these subsets, and the subset
results were compared with the results for all families.
As reported in the GENECARD study-design paper, all
sites were remarkably similar with respect to the distri-
bution of well-accepted CAD risk factors (Hauser et al.
2003). The distribution of families from each site con-
tributing to each subset is included in table 1.
Results
After the exclusions noted above, 420 families with
early-onset CAD passed the pedigree QC screen and
linkage analysis was performed by use of 395 micro-
satellite markers that passed the marker QC screen. Fig-
ure 1 shows the two-point MLOD results for all 395
markers arranged in marker-map order. Table 2 shows
the maximum multipoint LOD* linkage and location
estimates (in cM) for each chromosome. (Tables showing
the two-point results and multipoint linkage plots for
all chromosomes are available on the Duke Center for
Human Genetics Web site.) In the overall GENECARD
family sample, six regions were identiﬁed with a two-
point MLOD score of 11.5 (chromosomes 1q25, 3q13,
5q31, 10p15, 17q25, and 19p13) (see ﬁg. 1), and four
regions were identiﬁed with a multipoint LOD* score
11.0 (chromosomes 3q13, 5q31, 6q24, and 7p15) (see
table 2). By use of the criteria for follow-up described
above, two regions were identiﬁed. Chromosome 3q13
achieved an MLOD score of 2.3 at D3S2460 and a
LOD* score of 3.5 near D3S2460 at 140 cM (ﬁg. 2A).
The pairs-score LOD score was 3.28, and the empirical
P value for this result was !.001. The genomewide sig-
niﬁcant LOD score ( ) under the null hypothesisP ! .05
of no linkage for the set of all families was 2.70, and
thus the chromosome 3q13 region meets the criteria for
genomewide signiﬁcance. Chromosome 5q31 achieved
an MLOD score of 1.57 at D5S816 and a LOD* score
of 1.4 at 154.5 cM (ﬁg. 2B). The pairs-score LOD score
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Figure 1 Parametric LOD scores for affected subjects, allowing for genetic heterogeneity (MLOD). Results for all 395 markers typed in
the GENECARD study are shown for four groups: all families (squares), families with ACS (stars), families with ADL (triangles), and families
with NDIA (circles).
was 1.37, with an empirical P value of .081. The chro-
mosome 5q31 region did not achieve genomewide sig-
niﬁcance. For the other regions withMLOD scores 11.5,
the multipoint LOD* results did not reach the cut point
of 1.0, and, for the regions on chromosomes 6 and 7
with LOD* scores 11.0, the MLOD result did not reach
1.5 (tables 2 and 3).
The subset of patients with ACS gave two regions
withMLOD scores 11.5 (chromosomes 1q25 and 3q13)
and three regions with LOD* scores 11.0 (chromosomes
1q25, 3q13, and 19p13), with the regions on chro-
mosomes 1 and 3 meeting the criteria for follow-up.
The region on chromosome 1q25 achieved an MLOD
result of 2.44 at D1S518, with a LOD* result of 2.17
nearby at 202.4 cM (ﬁg. 2C). It is interesting that the
Merlin pairs-score LOD score, although maximizing at
the same location, was somewhat higher—2.85, with
an empirical P value of .006. The locus-counting meth-
od gave a genomewide signiﬁcant LOD score of 2.70
( ), under the null hypothesis of no linkage. TheP ! .05
region on chromosome 3 provided maximum LOD
scores at the same location as in the overall group, with
a maximum LOD score of 3.16 and an empirical P value
of .002. Both of these regions met the criteria for ge-
nomewide signiﬁcance in the subset of patients with
ACS.
The subset of patients with ADL gave two regions
withMLOD scores 11.5 (chromosomes 1q23 and 7p14)
and ﬁve regions with LOD* scores 11.0 (chromosomes
1p36, 6p12, 7p14, 17q25, and 18q21). The chromo-
some 7p14 MLOD score was 1.87 at D7S2846, and
the maximum LOD* score was 1.61 at 55.3 cM (em-
pirical P value p .061). The LOD score cutoff for ge-
nomewide signiﬁcance was 2.80.
The subset of patients with NDIA provided six
regions with MLOD scores 11.5 (chromosomes 3q13,
10p15, 16p13, 17q25, 19p13, and 20q13) and seven
regions with LOD* scores 11.0 (chromosomes 1p22,
3q13, 7p21, 14q11, 18q11, 19p13, and 20q13). Again,
the results on chromosome 3 were consistent with the
results in the overall group, with an MLOD score of
1.59 at D3S2460 and a LOD* score of 2.42 at 140 cM
(empirical P valuep .025). The region on chromosome
19 gave an MLOD score of 1.98 at D19S252, with a
LOD* score of 1.72, also at D19S252 (44 cM). How-
ever, the Merlin pairs-score LOD score was only 0.53,
with an empirical P value of .364. Although chromo-
some 20 provided LOD scores above the cut points for
each analysis, the locations were 110 cM apart:
at D20S102 (90.4 cM) and LOD* pMLODp 1.50
1.08 at 102 cM. Again, none of the regions in the subset
of patients with NDIA met the criteria for genomewide
signiﬁcance ( ), with a LOD score cutoff of 2.80.P ! .05
The results on chromosome 3 are particularly notable
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Table 2
Multipoint Maximum LOD Scores (and Location of Maximum in cM) on Each Chromosome for
GENECARD Families
CHROMOSOME
MAXIMUM LOD SCORE (AND LOCATION IN CM) FOR
All Families
(n p 420)
Families with ACS
(n p 228)
Families with ADL
(n p 146)
Families with NDIA
(n p 274)
1 .95 (198) 2.17 (202) 1.20 (3) 1.11 (62)
2 .31 (229) .39 (46) .77 (44) .54 (245)
3 3.50 (140) 3.16 (140) .54 (121) 2.42 (140)
4 .36 (189) .56 (180) .31 (189) .95 (189)
5 1.39 (154) .82 (16) .31 (98) .98 (153)
6 1.00 (142) .84 (160) 1.08 (69) .33 (140)
7 1.04 (32) .77 (194) 1.61 (55) 1.00 (32)
8 .59 (114) .42 (119) .36 (116) .53 (108)
9 .04 (106) .56 (106) .04 (115) .07 (80)
10 .09 (7.9) .13 (5) .30 (152) .26 (8)
11 .00 (…) .23 (12) .45 (50) .02 (12)
12 .25 (163) .27 (163) .89 (32) .45 (140)
13 .01 (114) .12 (114) .03 (103) .00 (…)
14 .62 (0) .38 (0) .70 (71) 1.06 (4)
15 .06 (16.7) .13 (17) .03 (17) .00 (…)
16 .20 (21) .79 (21) .17 (82) .37 (21)
17 .97 (123) .67 (123) 1.17 (123) .76 (123)
18 .97 (51) 1.01 (51) 1.14 (75) 1.20 (54)
19 .86 (44) .35 (44) .66 (44) 1.72 (44)
20 .67 (102) .42 (90) .23 (102) 1.08 (102)
21 .18 (58) .23 (55) .00 (…) .05 (35)
22 .05 (14) .21 (36) .38 (24) .31 (0)
X .04 (60) .14 (60) .00 (…) .00 (…)
NOTE.—LOD* values 11.0 are in bold italics.
because the evidence for linkage was strong and con-
sistent (multipoint at 140 cM; empiricalLODp 3.50
P value !.001) in the overall sample, as well as in phe-
notypic subsets (ﬁg. 2A). This region meets the criteria
for genomewide signiﬁcance ( ) in the set of allP ! .05
families, as well as in the subset of patients with ACS.
Furthermore, the LOD score from the multipoint anal-
ysis exceeded the LOD score from the two-point anal-
ysis, which suggests that the markers surrounding
D3S2460 increase the evidence for linkage. The peaks
were broad, with LOD scores consistently 11.0 from
D3S2406 to D3S2322 (112–146 cM) for all families,
as well as for the families with ACS and NDIA. The
families with ADL provided no evidence for linkage in
this region on chromosome 3. However, the LOD score
in all families was higher than the LOD score in any of
the phenotypic subsets, which suggests that the evidence
for linkage resides in the collection of all GENECARD
families.
The evidence for linkage on chromosome 5 (ﬁg. 2B)
was also stronger in the entire GENECARD sample set
than in any of the subsets. However, the evidence ap-
pears to derive predominantly from the families with
NDIA. The region was large, fromD5S505 toD5S1471,
covering nearly 50 cM, with ﬂat LOD scores across this
region. Furthermore, the microsatellite marker map was
less dense in this region, with an intermarker distance
of 120 cM between D5S1471 and D5S1354, which sug-
gests that adding more markers will better deﬁne the
linkage region.
The results for chromosome 1 (ﬁg. 2C) illustrate that
phenotypic stratiﬁcation may increase evidence for link-
age in genetically homogeneous subgroups in genomic
regions with modest evidence for linkage in the entire
sample set. Analyses of this chromosome yielded LOD
scores above the cut points for several strata; however,
the location estimates were very different. The results
for the entire GENECARD sample were modest, with
the maximum LOD score (LOD* p 0.95) at 197 cM.
When stratiﬁed by ACS, this modest maximum in the
overall group became a well-deﬁned LOD* peak, with
a maximum of 2.17. It is interesting that the Merlin
pairs-score LOD score was somewhat larger (2.85) and
met the criteria for genomewide signiﬁcance ( )P ! .05
in the families with ACS. This difference suggests con-
siderable variability in linkage information, perhaps re-
lated to family size. Analysis of this region on chro-
mosome 1 has revealed a gene for familial combined
hyperlipidemia (FCH), upstream transcription factor
USF1. To evaluate whether this peak was a result of a
subset of families with FCH, we evaluated lipid values
in the GENECARD families and identiﬁed 12 families
Figure 2 Multipoint nonparametric LOD score (LOD*) curves for all of the GENECARD families (solid lines) and for the three phenotypic
subsets (dashed lines [see legend]). Marker names and locations are indicated across the top. A, Chromosome 3. B, Chromosome 5. C,
Chromosome 1.
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with lipid values characteristic of FCH. These 12 fam-
ilies did not account for the linkage evidence on chro-
mosome 1, either as a group or individually. A LOD*
score of 1.20 at 2.7 cM in the group with ADL and a
LOD* score of 1.11 at 62 cM in the group with NDIA
suggest the possibility of three distinct regions of linkage
on chromosome 1.
Discussion
We have completed the ﬁrst phase of the genetic analysis
of CAD in 420 of the GENECARD families. The most
signiﬁcant result was a nonparametric multipoint LOD
score of 3.5 on chromosome 3q13, which meets the cri-
teria for genomewide signiﬁcance. Regions of chromo-
some 3q have been implicated in three other genome
screens for CAD (Francke et al. 2001; Broeckel et al.
2002; Harrap et al. 2002). However, in each of these
genome screens, the evidence of linkage to CAD is 160
cM distal to the peak in the GENECARD analysis, as
estimated by a meta-analysis (Chiodini and Lewis 2003).
It is interesting that this peak is also located in a region
that was identiﬁed in a genome screen of metabolic syn-
drome (Kissebah et al. 2000). Quantitative-trait linkage
analysis of plasma lipids has shown evidence of linkage
with triglyceride-HDL ratio, which provides a LOD
score of 1.8 in our peak region (Shearman et al. 2000).
There is also evidence for linkage to HDL itself (Im-
peratore et al. 2000; Coon et al. 2001) and fractionated
low-density lipoprotein (LDL) particles (Rainwater et al.
1999) in this region. The location of these QTL linkage
results in the proximity of the GENECARD peak is par-
ticularly interesting, since there is very little evidence for
linkage in the subset of patients with ADL. Together
these results provide consistent evidence that one or
more genes for CAD reside on chromosome 3q.
In addition to the chromosome 3 region, several other
regions of linkage include interesting candidate genes.
Despite the small numbers of families with apparent
FCH in the GENECARD sample, it would be useful to
examine the USF1 gene in patients with CAD (Paju-
kanta et al. 2004). Also in the 1q region are the C-
reactive protein (CRP) precursor locus and the P-selec-
tin and E-selectin loci, all excellent candidates for
early-onset CAD, especially in the context of ACS.
There is evidence for a locus on chromosome 1q from
QTL linkage analysis of lipid phenotypes (Shearman et
al. 2000; Broeckel et al. 2002) and from genome screens
of diabetes (Wiltshire et al. 2001; Hsueh et al. 2003;
Xiang et al. 2004) at approximately the same location
as the GENECARD 1q peak. However, the evidence in
the accumulated CAD scans performed to date is not
nearly as compelling for chromosome 1q as it is for
chromosome 3q.
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Table 3
Support Intervals for Linkage Peaks Identiﬁed in the
GENECARD Study for GENECARD Families
Chromosomal Region
and Family Subset(s) LOD*
1-LOD Unit Down
Support Interval
(cM)
3q13:
All families 3.50 134–152
Families with ACS 3.16 134–152
Families with NDIA 2.42 112–154
5q31:
All families 1.4 138–205
1q25:
Families with ACS 2.17 194–217
7p14:
Families with ADL 1.61 42–71
19p13:
Families with NDIA 1.72 22–35
To date, there have been ﬁve published genome
screens for CAD (Pajukanta et al. 2000; Francke et al.
2001; Broeckel et al. 2002; Harrap et al. 2002; Wang
et al. 2004) that have highlighted six chromosomal
regions in addition to 3q. The GENECARD families did
not provide consistent evidence of linkage at 2q21-22
or Xq23-26 (Pajukanta et al. 2000), 2q36 (Harrap et
al. 2002), or 14q (Broeckel et al. 2002). For the region
on 16p13 identiﬁed by Francke et al. (2001), MLOD
scores of 1.16, 1.23, and 1.65 (marker D16S764) were
obtained in all GENECARD families, families with
ACS, and families with NDIA, respectively. However,
these LOD scores achieved neither empirical P values
!.05 nor genomewide signiﬁcance. In addition, the mul-
tipoint analysis did not provide similar evidence for
linkage (LOD* p 0.20) at this locus. A recent study
by Wang et al. (2004) identiﬁed a strong signal at chro-
mosome 1p34-36 in a set of families with early-onset
MI, in approximately the same region on chromosome
1 as the peak in the GENECARD subset of patients
with ADL. As a group, these linkage studies do not
provide consistent evidence for linkage in any single
region, although consistencies are seen across pairs of
studies. Possible reasons for the differences in linkage
evidence for these regions include differences in the ge-
netic maps and marker density, as well as phenotypic
or population differences, such as genetic heterogeneity,
which may lead to variable evidence for linkage across
the ﬁve studies. Additional ﬁne mapping in these regions
will be required to clarify the linkage evidence in the
GENECARD families. Given the results from the strat-
iﬁed analysis in the GENECARD study, as well as the
differences among the various genome screens, it is
likely that close attention to the clinical and metabolic
characteristics of CAD will be required.
Through our subgroups of patients with CAD, we
have attempted to address some of the heterogeneity
believed to be behind the difﬁculties in replication of
genetic studies of CAD. Although we hope that this
strategy will allow genetic effects to be more easily de-
tected in a homogeneous subgroup, we also run the risk
of reducing statistical power in our sample, as well as
increasing the variability in the results, as we observed
when the MLOD, LOD*, and Merlin pairs-score sta-
tistics were compared. The addition of another set of
400 families, along with collaboration among the dif-
ferent groups to identify phenotypic characteristics re-
lated to linkage evidence, provides hope that we can
establish regions of consistency and detect smaller ge-
netic effects. Furthermore, understanding how pheno-
typic heterogeneity relates to evidence for linkage will
provide more homogeneous subsets in which to perform
additional genetic studies. More analyses, including or-
dered subset analysis (Hauser et al. 2004) and quanti-
tative-trait linkage analysis, will be required to under-
stand the possible relationship between evidence for
linkage and metabolic risk factors such as lipid levels
and insulin resistance. The relationships will need to be
examined not only within the GENECARD families but
also across the different family sets assembled for anal-
ysis of CAD (Pajukanta et al. 2000; Francke et al. 2001;
Broeckel et al. 2002; Harrap et al. 2002; Wang et al.
2004), hyperlipidemias (Naoumova et al. 2003; Paju-
kanta et al. 2004), metabolic syndrome (Kissebah et al.
2000; Tang et al. 2003), and diabetes (Ghosh et al.
2000; Watanabe et al. 2000; Du et al. 2001; Wiltshire
et al. 2001; Hsueh et al. 2003; Xiang et al. 2004), con-
ditions that may share genetic factors.
Review of the GENECARD family histories reveals
a signiﬁcant burden of disease. The individuals sampled
represent the CAD survivors, and thus we are not able
to include individuals in whom CAD presents as sudden
death. This is a limitation in any of the CAD or MI
genome screens. One way to examine the full spectrum
of CAD is to study the offspring of the GENECARD
probands and siblings prior to the onset of disease.
These offspring are at very high risk of CAD but have
not had clinical symptoms. By studying the offspring
prospectively, we can evaluate the risk of sudden death.
In addition to facilitating the study of the genetic basis
for CAD, this approach will also allow us to examine
the metabolic risk factors prior to treatment that appear
to contribute to CAD in these families (Jomini et al.
2002; Hauser et al. 2003).
This work represents one of the largest systematic
analyses of the genetics of CAD and provides a solid
basis for future candidate-gene analysis. The region
3q13 provides strong evidence for the existence of genes
for CAD in the GENECARD families. Interesting results
were also obtained for chromosome 5q31 and 1q25,
although work remains to be done to establish the ge-
netic effects in these regions. The genes ultimately iden-
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tiﬁed in these regions may drive or contribute to major
pathophysiological processes that lead to CAD—pro-
cesses that are either already established or hitherto un-
recognized. A greater understanding of the genetic basis
of the disease could potentially lead to the development
of novel preventive or therapeutic strategies for CAD.
Fine mapping, candidate-gene analyses, and analyses of
phenotypic heterogeneity are under way and represent
the next steps toward the realization of that potential.
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